Cardiac Biomarkers Market Statistics
The global cardiac biomarkers market is set to grow at a CAGR of 11.3%, touching the market value of USD 26.33bn in 2027, while it was valued at USD 13.15.
These biomarkers help in the diagnosis of cardiac diseases and provide information about the effectiveness of treatments. Different types of cardiac markers can diagnose a specific type of heart condition.
Cardiac biomarkers are substances in the blood that are indicative of disease or risk of disease. In clinical practice, the most commonly used biomarkers are high-sensitivity cardiac troponin, N-terminal pro-B-type natriuretic peptide, and Myoglobin. However, there is always a need for better and more precise biomarkers to diagnose cardiac diseases.
Myocardial Infarction to Boost Demand
Biomarkers have been revolutionizing cardiac diagnosis and treatment and evolving over the decades. Biomarkers such as Troponin I and T were introduced to bring out a change in the field of cardiology. Biomarkers such as Creatine Kinase MB isoform and Cardiac Troponin are used to detect acute myocardial infarction. Recently, more sensitive troponin assays have been introduced to rectify the weakness of the 12-hour wait to the peak. These two biomarkers can even detect early-stage acute myocardial infarction, which further may boost the global cardiac biomarkers.
Further, PCR devices and ELISA kits are used for detecting various cardiac diseases and conditions, with PCR devices being the most common tool used in laboratories across the globe. Additionally, the rising prevalence of hereditary diseases is some other factor that is likely to drive the growth of the cardiac biomarkers market.
Nanoscale Technology to Drive Cardiac Biomarkers Market
Although there has been tremendous growth in the cardiology field’s diagnostics sector, there is still a need to detect many diseases earlier than the advanced stage. Nanoscale technologies have been identified to overcome this weakness and enhance the practical usage of diagnostic tools in cardiology, owing to their unique features. The ideal cardiac biomarker with nanotechnologies has reasonable specificity and optimal sensitivity, which further is anticipated to bolster the demand for cardiac biomarkers. Nanotechnologies can be applied to electrochemiluminescence (ECL), and electrochemical (EC) due to their excellent biocompatibility, and electrical properties, thus, driving the global cardiac biomarkers market over the next few years.
The early markers that were identified as enzymes are also used for diagnosis sometimes, resulting in growth opportunities for the global cardiac biomarkers market.
During the outbreak of the Covid-19 pandemic, an unusual condition called Myocarditis was identified among Covid-19 positive patients. This resulted in the use of cardiac biomarkers, which indicates the growth potential in the future.
The major players are investing in the rapid development of biomarker test kits, paving the way for the expansion of the cardiac biomarkers market.
However, the limitation with biomarkers such as Troponin, which can only detect advanced stages of Myocadiac infarctions, is expected to impede the growth of the cardiac biomarkers market during the forecast period.
Nonetheless, the growing adoption of Rishabh Point-of-care biomarker tests that reduce the diagnosis time compared to conventional laboratory-based diagnosis might fast pace the growth in this market in the coming years.
Reduced Blood Flow to Incubate Acute Coronary Syndrome Segment
Based on indication, the global cardiac biomarkers market is bifurcated Myocardial infarction, Acute Coronary Syndrome, Congestive Heart Failure and others. However, Acute Coronary Syndrome is expected to hold the highest share in the global cardiac biomarkers market. The growth for this segment can be ascribed to the rising prevalence of Acute Coronary Syndrome. In the U.S alone, nearly 780,000 cases of Acute Coronary Syndrome are registered each year.
Simultaneously, Myocardial infarction is anticipated to expand, exhibiting a significant growth during the forecast years. The growth here can be attributed to Myocardial infarction being the leading cause of mortality across the globe; nearly 15% of mortality is due to MI every year worldwide.
On the basis of Biomarkers, the global cardiac biomarkers market is segmented into creatine kinase, B-type myoglobin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT), Troponin. However, the Troponin segment will dominate in the future. This is because of the increasing prevalence of cardiovascular diseases (CVDs) and the need for accurate diagnosis and treatment.
Regional Overview
Regionally, North America held the largest share of the cardiac biomarkers market in 2017, followed by Europe. The Asia Pacific region is projected to grow at the highest CAGR during the forecast period. This growth can be attributed to the growing geriatric population and the increasing prevalence of lifestyle-related disorders in this region. China dominates the Asia Pacific market for cardiac biomarkers due to its high economic growth. Japan is also one of the significant markets for cardiac biomarkers in the Asia Pacific. The country has witnessed an increase in cardiovascular disease cases recently due to increasing life expectancy coupled with changing lifestyles.
Forecasts suggest that cardiovascular diseases will continue to be a significant issue in Europe. The global cardiac biomarkers market in Europe is driven by the increasing prevalence of cardiovascular diseases, attributed to the rising geriatric population, changing lifestyle and dietary habits, and the growing awareness about heart health. This has led to an increase in demand for effective treatments such as cardiac biomarkers, which aid diagnosis and provide information about the effectiveness of treatment.
Competitive Landscape
One of the biggest trends in the cardiac biomarkers market is the increasing consolidation among key players. There has been a flurry of acquisitions and mergers in recent years as companies try to strengthen their position in this growing industry. For example, in 2016, Abbott Laboratories acquired Alere for $5.8 billion, giving Abbott a leading role in point-of-care diagnostics.1 Similarly, Roche Holdings purchased Ariosa Diagnostics for $1 billion in 20152, and Quest Diagnostics acquired Celera for $1.1 billion in 2013.
One of the key strategies companies use in the cardiac biomarkers market is to acquire other companies that offer complementary products or services. This allows them to expand their product offerings and better serve their customers. In recent years, there have been many acquisitions and mergers among companies in this industry.
Recent Developments
In 2021, Roche announced five new uses of key cardiac biomarkers in helping identify cardiovascular risks, diagnosis, and early treatment to reduce mortality.
In April 2022, Abbott received FDA approval for leadless pacemakers with virtual reality technology known as the new Avier Single Chamber pacemakers’ system, which will help in boosting cardiac rhythm management. Further, it is a minimally invasive device.
In April 2022, Thermo Fisher Scientific Inc. announced its Research and Development Facility expansion in India at Hyderabad. It will bring out job opportunities while adding to the economic growth of the country as well.
The common factors driving the cardiac biomarkers market increasing cardiovascular diseases, growing geriatric population, etc. the detection of
Some of the strong players in the global cardiac biomarkers include-
- Creative Diagnostics
- Beckman Coulter, Inc.
- Bio-Rad Laboratories, Inc.
- Thermo Fisher Scientific Inc.
- bioMérieux SA
- Hoffmann-La Roche AG
- Abbott
- Siemens AG
By Indication
Myocardial Infarction
- Congestive Heart Failure
- Acute Coronary Syndrome
By Biomarker
- Troponin
- Creatine Kinase-MB (CK-MB)
- Myoglobin
- B-type Natriuretic Peptide (BNP)
By End-User
- Speciality Clinics
- Hospitals
Regional Outlook
North America
- U.S.
- Canada
Europe
- U.K.
- Germany
- France
- Italy
- Spain
- Russia
- Greece
- The Netherlands
Asia Pacific
- Japan
- China
- India
Latin America
- Mexico
- Brazil
- Argentina
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Frequently Asked Question
What are the drivers for the cardiac biomarkers market?
The drivers for this market are the increasing prevalence of cardiovascular diseases such as myocardial infarction, acute coronary syndrome, etc., rising demand for personalized treatments and impact of COVID 19.
Which segment provides the most opportunity for growth?
By Indication Acute Coronary Syndrome is expected to hold the largest share while the Myocardial Infarction segment is anticipated to grow at a significant rate.
Who are the leading vendors operating in this market?
Thermo Fisher Scientific Inc., bioMérieux, SA F. Hoffmann-La Roche AG, Abbott, Creative Diagnostics, Beckman Coulter, Inc., and Bio-Rad Laboratories, Inc. are some of the leading vendors in the global cardiac biomarker market.
Which region is expected to witness significant demand for cardiac marker testing in the coming years?
The North American region is anticipated to dominate the global cardiac biomarkers market owing to its high penetration rate and higher healthcare expenditure per capita compared with other economies in this region. Asia Pacific (APAC) offers vast potential since it has large populations who suffer from cardiovascular diseases coupled by increased awareness about risks associated with such disorders among patients resulting in a greater number of diagnostic tests being conducted thereby providing lucrative growth prospects.
Table Of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Supply Chain Analysis
3.6. Investment Feasibility Matrix
3.7. Value Chain Analysis
3.8. PESTLE and Porter’s Analysis
3.9. Regulatory Landscape
3.9.1. By Key Regions
3.9.2. By Key Countries
3.10. Regional Parent Market Outlook
3.11. Production and Consumption Statistics
3.12. Import and Export Statistics
4. Global Cardiac Biomarkers Market Analysis 2017-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis, 2017-2021
4.2. Current and Future Market Size Value (US$ Mn) & Volume (Units) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Cardiac Biomarkers Market Analysis 2017-2021 and Forecast 2022-2032, By By Indication
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By By Indication, 2017-2021
5.3. Current and Future Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By By Indication, 2022-2032
5.3.1. Myocardial Infarction
5.3.1.1. Congestive Heart Failure
5.3.1.2. Acute Coronary Syndrome
5.3.2. By Biomarker
5.3.2.1. Troponin
5.3.2.3. Creatine Kinase-MB (CK-MB)
5.3.2.3. Myoglobin
5.3.2.4. B-type Natriuretic Peptide (BNP)
5.4. Y-o-Y Growth Trend Analysis By By Indication, 2017-2021
5.5. Absolute $ Opportunity Analysis By By Indication, 2022-2032
6. Global Cardiac Biomarkers Market Analysis 2017-2021 and Forecast 2022-2032, By By End User
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By By End User, 2017-2021
6.3. Current and Future Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By By End User, 2022-2032
6.3.1. Specialty Clinics
6.3.2. Hospitals
6.4. Y-o-Y Growth Trend Analysis By By End User, 2017-2021
6.5. Absolute $ Opportunity Analysis By By End User, 2022-2032
7. Global Cardiac Biomarkers Market Analysis 2017-2021 and Forecast 2022-2032, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By Region, 2017-2021
7.3. Current Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By Region, 2022-2032
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. East Asia
7.3.5. South Asia
7.3.6. Oceania
7.3.7. MEA
7.4. Market Attractiveness Analysis By Region
8. North America Cardiac Biomarkers Market Analysis 2017-2021 and Forecast 2022-2032, By Country
8.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
8.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
8.2.1. By Country
8.2.1.1. U.S.
8.2.1.2. Canada
8.2.2. By By Indication
8.2.3. By By End User
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By By Indication
8.3.3. By By End User
8.4. Key Takeaways
9. Latin America Cardiac Biomarkers Market Analysis 2017-2021 and Forecast 2022-2032, By Country
9.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
9.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Argentina
9.2.1.4. Chile
9.2.1.5. Peru
9.2.1.6. Rest of Latin America
9.2.2. By By Indication
9.2.3. By By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By By Indication
9.3.3. By By End User
9.4. Key Takeaways
10. Europe Cardiac Biomarkers Market Analysis 2017-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
10.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. Italy
10.2.1.3. France
10.2.1.4. U.K.
10.2.1.5. Spain
10.2.1.6. Russia
10.2.1.7. BENELUX
10.2.1.8. Rest of Europe
10.2.2. By By Indication
10.2.3. By By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By By Indication
10.3.3. By By End User
10.4. Key Takeaways
11. East Asia Cardiac Biomarkers Market Analysis 2017-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
11.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.2. By By Indication
11.2.3. By By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By By Indication
11.3.3. By By End User
11.4. Key Takeaways
12. South Asia Cardiac Biomarkers Market Analysis 2017-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
12.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Thailand
12.2.1.3. Malaysia
12.2.1.4. Indonesia
12.2.1.5. Rest of South Asia
12.2.2. By By Indication
12.2.3. By By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By By Indication
12.3.3. By By End User
12.4. Key Takeaways
13. Oceania Cardiac Biomarkers Market Analysis 2017-2021 and Forecast 2022-2032, By Country
13.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
13.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
13.2.1. By Country
13.2.1.1. Australia
13.2.1.2. New Zealand
13.2.2. By By Indication
13.2.3. By By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By By Indication
13.3.3. By By End User
13.4. Key Takeaways
14. MEA Cardiac Biomarkers Market Analysis 2017-2021 and Forecast 2022-2032, By Country
14.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
14.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
14.2.1. By Country
14.2.1.1. GCC
14.2.1.2. Rest of MEA
14.2.2. By By Indication
14.2.3. By By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By By Indication
14.3.3. By By End User
14.4. Key Takeaways
15. Key Countries Cardiac Biomarkers Market Analysis
15.1. U.S.
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2021
15.1.2.1. By By Indication
15.1.2.2. By By End User
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2021
15.2.2.1. By By Indication
15.2.2.2. By By End User
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2021
15.3.2.1. By By Indication
15.3.2.2. By By End User
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2021
15.4.2.1. By By Indication
15.4.2.2. By By End User
15.5. Argentina
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2021
15.5.2.1. By By Indication
15.5.2.2. By By End User
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. Â By Regional
16.3.2. Â By By Indication
16.3.3. Â By By End User
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Creative Diagnostics
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.1.5.2. Product Strategy
17.1.1.5.3. Channel Strategy
17.1.2. Beckman Coulter, Inc.
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.2.5.2. Product Strategy
17.1.2.5.3. Channel Strategy
17.1.3. Bio-Rad Laboratories, Inc.
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.3.5.2. Product Strategy
17.1.3.5.3. Channel Strategy
17.1.4. Thermo Fisher Scientific Inc.
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.4.5.2. Product Strategy
17.1.4.5.3. Channel Strategy
17.1.5. bioMérieux SA
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.5.5.2. Product Strategy
17.1.5.5.3. Channel Strategy
17.1.6. F. Hoffmann-La Roche AG
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.6.5.2. Product Strategy
17.1.6.5.3. Channel Strategy
17.1.7. Abbott
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.7.5.2. Product Strategy
17.1.7.5.3. Channel Strategy
17.1.8. Siemens AG
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.8.5.2. Product Strategy
17.1.8.5.3. Channel Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Request Free Sample
